# CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

> **NCT06687772** · PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 36 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Thiotepa
- **DRUG:** Carmustine
- **PROCEDURE:** Autologous Stem Cell Transplant
- **DRUG:** Anthracycline-based induction chemotherapy

## Key facts

- **NCT ID:** NCT06687772
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06687772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06687772, "CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06687772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*